Sun Y, Zhang R, Meng Y, Zhu L, Li M, Liu Z
Department of Pharmacy, First Affiliated Hospital of Bengbu Medical University, Bengbu 233003, China.
Department of Clinical Pharmacy, Bengbu Medical University, Bengbu 233003, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2024 May 20;44(5):810-817. doi: 10.12122/j.issn.1673-4254.2024.05.02.
To explore the neuroprotective effect of coenzyme Q10 and its possible mechanism in mice with chronic restraint stress (CRS).
Mouse models of CRS were treated with intraperitoneal injections of coenzyme Q10 at low, moderate and high doses (50, 100 and 200 mg/kg, respectively, =8), VX765 (a caspase-1 specific inhibitor, 50 mg/kg, =8), or fluoxetine (10 mg/kg, =8) on a daily basis for 4 weeks, and the changes in depression-like behaviors of the mice were assessed by sugar water preference test, forced swimming test and tail suspension test. The expression of glial fibrillary acidic protein (GFAP) in the hippocampus of the mice was detected using immunohistochemistry, and the number of synaptic spines was determined with Golgi staining. Western blotting was performed to detect the changes in the expressions of GFAP and pyroptosis-related proteins in the hippocampus, and the colocalization of neurons and caspase-1 p10 was examined with immunofluorescence assay.
Compared with the normal control mice, the mouse models of CRS showed significantly reduced sugar water preference and increased immobility time in forced swimming and tail suspension tests ( < 0.05), and these depression-like behaviors were obviously improved by treatment with coenzyme Q10, VX765 or FLX. The mouse models showed a significantly decreased positive rate of GFAP and lowered GFAP protein expression in the hippocampus with obviously decreased synaptic spines, enhanced expressions of GSDMD-N, caspase-1 and IL-1β, and increased colocalization of neurons and caspase-1 p10 (all < 0.05). All these changes were significantly ameliorated in the mouse models after treatment with Q10.
Coenzyme Q10 can alleviate depression-like behaviors in mice with CRS by down-regulating the pyroptosis signaling pathway.
探讨辅酶Q10对慢性束缚应激(CRS)小鼠的神经保护作用及其可能机制。
将CRS小鼠模型分为低、中、高剂量辅酶Q10组(分别为50、100和200 mg/kg,每组n = 8)、VX765组(一种半胱天冬酶-1特异性抑制剂,50 mg/kg,每组n = 8)或氟西汀组(10 mg/kg,每组n = 8),每天腹腔注射给药,持续4周。通过糖水偏好试验、强迫游泳试验和悬尾试验评估小鼠抑郁样行为的变化。采用免疫组织化学法检测小鼠海马中胶质纤维酸性蛋白(GFAP)的表达,用高尔基染色法测定突触棘的数量。采用蛋白质免疫印迹法检测海马中GFAP和焦亡相关蛋白表达的变化,用免疫荧光法检测神经元与半胱天冬酶-1 p10的共定位情况。
与正常对照小鼠相比,CRS小鼠模型的糖水偏好显著降低,强迫游泳和悬尾试验中的不动时间增加(P < 0.05),而辅酶Q10、VX765或氟西汀治疗可明显改善这些抑郁样行为。CRS小鼠模型海马中GFAP阳性率显著降低,GFAP蛋白表达降低,突触棘明显减少,GSDMD-N、半胱天冬酶-1和白细胞介素-1β表达增强,神经元与半胱天冬酶-1 p10的共定位增加(均P < 0.05)。Q10治疗后,CRS小鼠模型的所有这些变化均得到显著改善。
辅酶Q10可通过下调焦亡信号通路减轻CRS小鼠的抑郁样行为。